Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

October 15, 2026

Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube

SER-428 significantly reduced gastrointestinal abundance of clinically relevant pathogens in preclinical in vivo colonization models

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that preclinical data supporting the development of SER-428, an investigational oral liquid live biotherapeutic product (LBP) designed to reduce the risk of bloodstream infections (BSIs) in medically vulnerable patients following sepsis and antibiotic exposure, will be presented at IDWeek 2026, taking place October 21–24 in Washington, D.C.

Poster Details
Number: P-22
Title: SER-428, an Investigational Live Biotherapeutic Product (LBP) with a Novel Liquid Formulation, for Reduction of Bloodstream Infections in High-Risk Patients after Sepsis and Antibiotic Exposure
Session: Novel Agents
Date and Time: October 22, 12:15-1:30 pm EST
Location: Poster Hall B-C

SER-428 shares key strains and functions with SER-155, Seres' investigational LBP that successfully completed a Phase 1b study in patients undergoing allogeneic hematopoietic stem cell transplantation, demonstrating a 77% relative risk reduction in BSIs and a well-tolerated safety profile. SER-428, developed with support from a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), is designed to act in the gastrointestinal (GI) tract to prevent the colonization and overgrowth of pathogens, and to protect and increase mucosal epithelial barrier integrity, with the goal of reducing the risk of infection. Notably, SER-428 is a liquid formulation for the LBP modality that enables dosing in patients who cannot take oral capsules, including critically ill patients who receive nutrition and medications via feeding tube.

"Patients admitted to the medical intensive care unit with sepsis remain at high risk for subsequent serious infections, particularly after antibiotic exposure disrupts the gastrointestinal microbiome and allows pathogenic bacteria to proliferate," said Matthew Henn, Ph.D., President and Chief Scientific Officer of Seres Therapeutics. "SER-428 builds on our positive clinical experience with SER-155 and is designed specifically with the needs of critically ill patients in mind. The findings presented at IDWeek provide important preclinical support for both the biological activity and the formulation characteristics of SER-428 as we advance the clinical development plans for the program. We appreciate the long-standing support from CARB-X, which has allowed this work to progress."

In preclinical in vivo pathogen colonization models, oral administration of SER-428 led to up to a 1,000- fold reduction of *Enterococcus faecium* and *Klebsiella pneumoniae*. These findings support the potential of SER-428 to reduce GI pathogen abundance, bloodstream infections, and antimicrobial resistance in high-risk patients. The SER-428 liquid formulation was stable, including during the intended in-use period and following simulated feeding tube delivery.

Seres is currently designing a Phase 1b open-label trial, in collaboration with Daniel E. Freedberg, M.D., M.S., of Columbia University, and in consultation with CARB-X, to evaluate SER-428 in Medical Intensive Care Unit (MICU) patients at high risk of infection. Further clinical development of SER-428 will be progressed pending funding from grants or other sources.

IDWeek is an annual meeting organized by a collaboration of professional organizations, including the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).

About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products (LBP), designed to address unmet needs in oncology that can lead to interruption to patients' cancer care and/or mortality, and to treat inflammatory and immune (I&I) diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, an investigational cultivated multi-strain biotherapeutic, which has received Breakthrough Therapy and Fast Track designations, is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT), and is Phase 2 ready, pending receipt of funding. SER-155 is also being developed to address immune checkpoint inhibitor-related enterocolitis (irEC) to provide an immunosuppressive-free alternative and enable patients to continue their ICI cancer therapy. Having recently reported promising results from an investigator sponsored trial, Seres is evaluating the design of a Phase 2 study in irEC. The Company is advancing IND-enabling studies for SER-603, which is in development for inflammatory bowel disease. Mechanistically, Seres' biotherapeutics target the mucosal epithelial barrier-immune interface and are optimized to modulate host function to increase mucosal epithelium integrity, induce immune homeostasis, and prevent the colonization and

overgrowth of harmful bacteria in the GI tract. For more information, please visit www.serestherapeutics.com.

About CARB-X
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is the world's leading non-profit partnership accelerating the research and development of innovative products to prevent, diagnose and treat bacterial infections and address the global threat of antimicrobial resistance. CARB-X pairs non-dilutive funding with comprehensive technical and scientific support, resulting in supported projects being five times more likely to advance into clinical development than comparable projects that did not receive CARB-X support. Research reported in this press release is partially supported by CARB-X. CARB-X is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under agreement number 75A50122C00028 and by awards from Wellcome (WT224842), the UK Department of Health and Social Care's Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Gates Foundation, Germany's Federal Ministry of Research, Technology and Space (BMFTR), the Novo Nordisk Foundation, Italy's Ministry of Economy and Finance (MEF), Japan's Ministry of Health, the European Commission's DG Health Emergency Preparedness and Response Authority (DG HERA), and KfW Development Bank. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product development. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or its funders

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: the anticipated content and timing of upcoming presentations and conferences; SER-155, SER-428, and their intended uses and benefits; our clinical development plans for SER-155 and SER-428; the timing and results of clinical studies and data readouts; current or future product candidates and their potential impacts and outcomes; current or future grants or funding from CARB-X or other sources; the anticipated timing of any of the foregoing; and other statements that are not historical fact.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) our need for additional funding; (2) our ability to continue as a going concern; (3) we have incurred significant losses, are not currently profitable and may never become profitable; (4) our cost reduction actions may not achieve their intended benefits, including an extended cash runway; (5) our limited operating history; (6) we may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company; (7) we have in the past and may in the future receive notice of the failure to satisfy a continued listing rule from The Nasdaq Stock Market LLC; (8) our novel approach to therapeutic intervention; (9) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (10) our ability to achieve market acceptance necessary for commercial success; (11) the competition we will face; (12) our ability to protect our intellectual property; (13) impact of our recent management transitions and appointments and our ability to retain key personnel; and (14) disruptions at the FDA or other government agencies. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission (SEC) on August 5, 2026, as well as our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor and Media Contact:
IR@serestherapeutics.com

Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com